Observational studyEpilepsia2026
Ketamine in super-refractory status epilepticus: Combined value of inflammatory biomarkers and EEG features.
Observational study in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the efficacy and safety of intravenous ketamine in a cohort of patients with super-refractory status epilepticus (SRSE) and to explore whether specific clinical, laboratory, and EEG patterns could predict treatment response.
methodsThis single-center retrospective observational study included all adult patients treated with intravenous ketamine for SRSE between August 2020 and September 2025, at the University Hospital of Trieste. Demographic, clinical, laboratory, and EEG data were collected from medical records. EEG recordings obtained during and after ketamine infusion were analyzed according to American Clinical Neurophysiology Society (ACNS) terminology. Associations between baseline characteristics, clinical outcomes, and laboratory and EEG patterns were examined using univariate statistics, and an exploratory EEG severity score, the KEOS (Ketamine EEG Outcome Score), was constructed to assess predictive accuracy.
resultsTwelve patients met the inclusion criteria. The sustained response rate, defined as seizure cessation without recurrence after complete anesthetic withdrawal, was 58%. Non-responders exhibited a profound hyperinflammatory state at the onset of status epilepticus, with significantly higher levels of composite indices such as the neutrophil-to-lymphocyte ratio (NLR), Systemic Inflammation Response Index (SIRI), and Systemic Immune-Inflammation Index (SII). Moreover, a "beta background" pattern was significantly more frequent among responders, whereas discontinuous or burst-suppression backgrounds were associated with poor outcomes. The KEOS demonstrated excellent discrimination (area under the curve [AUC] = .97, sensitivity = 100%, specificity = 85.7%). Adverse events were mild, with transient liver enzyme elevation in 42% of patients. SIGNIFICANCE: Intravenous ketamine showed moderate efficacy and a favorable safety profile in this SRSE cohort. The identification of specific EEG signatures together with systemic inflammatory biomarkers suggests the potential for a more biologically informed approach to ketamine monitoring and treatment optimization. However, given the limited sample size, these findings should be interpreted as hypothesis-generating and warrant validation in larger, prospective multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.